SZABO SCANDIC

Part of Europa Biosite

# Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

## Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

## Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand


**SZABO-SCANDIC HandelsgmbH**

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Order online now!

www.rockland.com
tech@rockland.com
+1 484.791.3823

Datasheet for MB-077-0050

# 10X RIPA Lysis Buffer

## Overview

| | |
|---|---|
| **Description:** | 10X RIPA Lysis Buffer - MB-077-0050 |
| **Item No.:** | MB-077-0050 |
| **Size:** | 50 mL |
| **Applications:** | ChIP, IP, WB, Other |

## Product Details

| | |
|---|---|
| **Background:** | RIPA (Radio-Immunoprecipitation Assay) Lysis Buffer enables rapid, efficient cell lysis and solubilization of proteins from both adherent and suspension cultured mammalian cells. It has long been a widely used lysis and wash buffer for small-scale affinity pull-down applications, such as immunoprecipitation, since most antibodies and protein antigens are not adversely affected by the components of this buffer. In addition, RIPA Lysis Buffer minimizes non-specific protein-binding interactions to keep background low, while allowing most specific interactions to occur, enabling studies of relevant protein-protein interactions. The following RIPA Lysis Buffer components have the following effects: Tris-HCl is a buffering agent prevents protein denaturation, NaCl is a salt that prevents non-specific protein aggregation, IGEPAL is a non-ionic detergent to extract proteins; Na-deoxycholate and SDS are ionic detergents to extract proteins; and sodium azide is a bacteriostatic agent added to retard bacterial growth. RIPA Lysis Buffer is supplied as a ready-to-use solution that requires no preparation. We suggest that the user add protease and phosphatase inhibitors not included with this product prior to use. |
| **Synonyms:** | 10X RIPA Lysis Buffer, RIPA (Radio-Immunoprecipitation Assay) Lysis Buffer |

## Target Details

| | |
|---|---|
| **Purity/Specificity:** | This product was aseptically filtered through a Millipore 0.22 micron filter into clean, pre-sterilized containers. The product was tested on trypticase soy agar for 24 hours, 48 hours and 72 hours and was found to be negative for bacteria. |
| **Relevant Links:** | • RIPA Lysis Buffer Procedure |

## Application Details

| | |
|---|---|
| **Tested Applications:** | ChIP, IP, WB |

| | |
|---|---|
| **Suggested Applications:** | Other (Based on references) |
| **Application Note:** | This product is 10X concentrated stock solution. Dilute to 1X prior to use. 1X RIPA Lysis Buffer is intended for the extraction of cellular proteins for the efficient lysis of cells and solubilization of protein, while minimizing protein degradation and maintaining protein immunoreactivity and biological activity. We recommend using 1.0 ml of RIPA Lysis Buffer to lyse 0.5 to 5 x 10E7 adherent mammalian cells. This buffer contains ionic detergents and may not be suitable for kinase enzymes, if these enzymes are easily denatured. Do not add phosphatase inhibitors when preparing lysates for phosphatase assays. 1X RIPA lysis buffer consists of 50 mM Tris HCl, 150 mM NaCl, 1.0% (v/v) IGEPAL® CA-630, 0.5% (w/v) Sodium Deoxycholate, 1.0 mM EDTA, 0.1% (w/v) SDS and 0.01% (w/v) sodium azide at a pH of 7.4. This buffer was meticulously prepared using ultra pure reagents dissolved in highly polished pharmaceutical grade deionized water.<br><br>Protease and phosphatase inhibitors are recommended but not included in product composition.<br><br>Recommended final concentrations of protease inhibitors:<br>1.0 mM Phenylmethylsulfonyl fluoride (PMSF)<br>10 µM Leupeptin<br>0.1 µM Aprotinin<br>1.0 µM Pepstatin<br><br>Recommended final concentrations of phosphatase inhibitors:<br>1.0 mM Na3VO4<br>1.0 mM NaF |
| **Assay Dilutions:** | All assays should be optimized by the user. Recommended dilutions (if any) may be listed below. |
| **IP:** | User Optimized |
| **WB:** | User Optimized |

## Formulation

| | |
|---|---|
| **Physical State:** | Liquid (sterile filtered) |
| **Concentration:** | 10X |
| **Buffer:** | See application note. |
| **Preservative:** | 0.01% (w/v) Sodium Azide |
| **Stabilizer:** | None |

## Shipping & Handling

| | |
|---|---|
| **Shipping Condition:** | Ambient |
| **Storage Condition:** | Store container at room temperature (18° to 26° C) prior to opening. Protect from light (store in the dark). |
| **Expiration:** | Expiration date is six (6) months from date of receipt. |

## Images


**Bottle**
10X RIPA Lysis Buffer

## References


- Qi Y et al. Down-regulating miR-217-5p Protects Cardiomyocytes against Ischemia/Reperfusion Injury by Restoring Mitochondrial Function via Targeting SIRT1. *Inflammation.* (2021)
- Noh BJ et al. Pathogenetic implications of early growth response 1 in Ewing sarcoma. *Pathology.* (2019)
- Yong Zhao et al. Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth. *Biochem Pharmacol.* (2015)
- Zhuo Wang et al. Chronic intermittent low-level transcutaneous electrical stimulation of auricular branch of vagus nerve improves left ventricular remodeling in conscious dogs with healed myocardial infarction. *Circ Heart Fail.* (2014)
- Uemura K et al. Early short-term vagal nerve stimulation attenuates cardiac remodeling after reperfused myocardial infarction. *J Card Fail.* (2010)


## Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.